Search for new products by date added, alphabetically, or by pharmacological action.
New products are an essential component of our range. Introductions are made on an ongoing basis, with hundreds of new small molecules and peptides being added every year. Our aim is to find the latest, otherwise unobtainable research tools, and bring them to the market as quickly as we can. New products can be identified throughout the Tocris website by the New symbol.
If you can't find what you are looking for we welcome new product suggestions. If you would like to be kept informed about new products by email, please sign up for our monthly e-alert service.
| Cat. No. | 产品名称/活性 | Date Added |
|---|---|---|
| 6863 | N6-Cyclohexyladenosine | Nov 2019 |
| High affinity A1 receptor agonist | ||
| 6870 | AZ 12799734 | Nov 2019 |
| Potent TGF-βRI inhibitor | ||
| 7013 | OptoBI-1 | Nov 2019 |
| Photoswitchable TRPC3/6/7 agonist | ||
| 7066 | RCGD 423 | Nov 2019 |
| gp130 modulator; activates JAK/STAT signaling | ||
| 7044 | (±)-α-Lipoic acid | Nov 2019 |
| Liquid-liquid phase separated condensate modifier; reduces stress granule formation | ||
| 6481 | AP 14145 hydrochloride | Nov 2019 |
| KCa2 channel negative allosteric modulator | ||
| 4265 | AS 1842856 | Nov 2019 |
| Potent and selective Foxo1 inhibitor; orally bioavailable | ||
| 6895 | VU 0424465 | Oct 2019 |
| Potent mGlu5 positive allosteric modulator and agonist; binds allosteric site with high affinity | ||
| 7065 | Kainic acid (synthetic) | Oct 2019 |
| Kainate agonist; excitant and neurotoxin | ||
| 7045 | (±)-α-Lipoamide | Oct 2019 |
| Phase-separated condensate modifier; orally bioavailable | ||
| 6574 | Fluorescein-NAD+ | Oct 2019 |
| Fluorescent NAD+; substrate for ADP-ribosylation for use in PARP assays | ||
| 6982 | Cyclosporin H | Oct 2019 |
| Viral transduction enhancer | ||
| 6936 | VZ 185 | Oct 2019 |
| Potent and selective BRD7/9 Degrader | ||
| 6932 | VU 0467485 | Oct 2019 |
| Potent and selective positive allosteric modulator of M4 receptors; orally bioavailable and brain penetrant | ||
| 6897 | P110 | Oct 2019 |
| Dynamin-related protein 1 (Drp1) inhibitor; cell-permeable | ||
| 6847 | TAT-GluA2 3Y | Oct 2019 |
| Inhibitor of AMPA receptor endocytosis | ||
| 6691 | LP 922056 | Oct 2019 |
| Notum inhibitor; activates Wnt signaling | ||
| 6974 | BMS 986094 | Oct 2019 |
| Prodrug of HCV RNA polymerase inhibitor 2'-C-methyl guanosine triphosphate; potent HCV replication inhibitor | ||
| 6940 | BTD | Oct 2019 |
| Selective TRPC5 activator | ||
| 6573 | Biotin-NAD+ | Oct 2019 |
| Biotinylated-NAD+; substrate for ADP-ribosylation | ||
| 7046 | 1,6-Hexanediol | Sep 2019 |
| Tool for probing liquid-liquid phase separation | ||
| 7027 | LY 2033298 | Sep 2019 |
| Selective positive allosteric modulator of M4 receptors; active in vivo; antipsychotic | ||
| 7006 | PDD 00017272 | Sep 2019 |
| Potent PARG inhibitor | ||
| 6427 | Tafluprost | Sep 2019 |
| Very high affinity FP receptor agonist | ||
| 6821 | ZAP 180013 | Sep 2019 |
| Zap70 inhibitor; inhibits interaction with ITAMs | ||
| 7005 | 4-Thiouridine | Sep 2019 |
| Photoreactive uridine analog for RNA sequencing | ||
| 5847 | ZLD 1039 | Sep 2019 |
| Potent and selective EZH2 inhibitor; orally bioavailable | ||
| 6970 | aTAG 2139 | Sep 2019 |
| Degrader of MTH1 fusion proteins for use within the aTAG system | ||
| 6797 | KLD 12 | Sep 2019 |
| Self-assembling peptide; forms hydrogel to support cell growth | ||
| 6764 | B 973B | Sep 2019 |
| Positive allosteric modulator of α7 nAChRs; analgesic | ||
| 6972 | A 1899 | Sep 2019 |
| Potent K2P3.1 (TASK-1) and K2P9.1 (TASK-3) blocker | ||
| 6950 | Thalidomide - linker 11 | Sep 2019 |
| Thalidomide-PEG3-ethylamine | ||
| 6889 | ML 418 | Sep 2019 |
| Kir 7.1 inhibitor; also inhibits Kir 6.2 | ||
| 6857 | BAY 293 | Sep 2019 |
| Potent KRas/SOS1 interaction inhibitor | ||
| 6899 | TH 257 | Sep 2019 |
| Potent and selective allosteric LIMK 1/2 inhibitor | ||
| 6888 | ML 402 | Sep 2019 |
| Selective TREK channel activator | ||
| 7020 | LDV | Sep 2019 |
| α4β1 (VLA-4) ligand | ||
| 6803 | MRK 740 | Sep 2019 |
| Potent PRDM9 inhibitor | ||
| 6937 | BSJ-04-132 | Sep 2019 |
| Selective Cdk4 degrader | ||
| 6980 | BAY 87-2243 | Sep 2019 |
| Mitochondrial complex I inhibitor | ||
| 6906 | BAY 293 Negative Control | Sep 2019 |
| Negative control for BAY 293 (Cat. No. 6857) | ||
| 6893 | VU 6005649 | Sep 2019 |
| Positive allosteric modulators of mGlu7 and mGlu8 receptors; also NK1 antagonist; brain penetrant | ||
| 6765 | JTP 103237 | Aug 2019 |
| Potent and selective monoacyglycerol acyltransferase 2 (MOGAT2) inhibitor | ||
| 6938 | BSJ-03-204 | Aug 2019 |
| Selective Cdk4/6 degrader | ||
| 6201 | J 2156 | Aug 2019 |
| Selective high affinity human sst4 agonist | ||
| 6994 | HODHBt | Aug 2019 |
| STAT5-SUMO protein-protein interaction inhibitor | ||
| 6978 | AZD 5363 | Aug 2019 |
| Potent pan-AKT inhibitor | ||
| 6619 | TFAX 488, SE | Aug 2019 |
| Green fluorescent dye; amine reactive | ||
| 6927 | Glucagon (Human, Porcine) | Aug 2019 |
| Endogenous glucagon receptor agonist | ||
| 6930 | Amphotericin B | Aug 2019 |
| Forms monovalent ion channels in lipid bilyers; antifungal | ||
| 6859 | FITM | Aug 2019 |
| Potent and selective negative allosteric modulator of mGlu1 receptors | ||
| 6922 | BSJ-Bump | Aug 2019 |
| Negative control for BSJ-03-123 (Cat. No. 6921) | ||
| 6921 | BSJ-03-123 | Aug 2019 |
| Selective Cdk6 degrader | ||
| 6623 | TFAX 546, SE | Aug 2019 |
| Yellow fluorescent dye; amine reactive | ||
| 6109 | Methylnaltrexone bromide | Aug 2019 |
| μ antagonist; peripherally restricted | ||
| 6054 | R162 | Aug 2019 |
| Glutamate dehydrogenase (GDH1) inhibitor | ||
| 5861 | ARN 726 | Aug 2019 |
| Potent N-acylethanolamine acid amidase (NAAA) inhibitor; NAAA activity-based protein profiling (ABPP) probe | ||
| 6902 | OLT 1177 | Jul 2019 |
| NLRP3 inflammasome inhibitor; disrupts inflammasome formation | ||
| 6823 | CycLuc 1 | Jul 2019 |
| Synthetic luciferase substrate; brain penetrant; displays NIR emission | ||
| 6954 | L-Buthionine sulfoximine | Jul 2019 |
| Irreversible γ-glutamylcysteine synthetase (γ-GCS) inhibitor; induces ferroptosis | ||
| 6776 | G5 | Jul 2019 |
| Ubiquitin isopeptidase inhibitor; induces apoptosis | ||
| 6751 | (R)-(-)-Ketamine hydrochloride | Jul 2019 |
| NMDA antagonist; antidepressant; may not display psychotomimetic or addictive side effects of (S)-ketamine | ||
| 6986 | EG 00229 trifluoroacetate | Jul 2019 |
| Neuropilin 1 (NRP1) receptor antagonist; inhibits VEGFA binding to NRP1 | ||
| 6886 | ML 67-33 | Jul 2019 |
| K2P2.1 (TREK-1), K2P10.1 (TREK-2) and K2P4.1 (TRAAK) channel activator | ||
| 6933 | CM 10 | Jul 2019 |
| ALDH1A inhibitor; depletes CD133+ cancer stem cells | ||
| 6920 | SAH-SOS1A | Jul 2019 |
| KRas/SOS1 interaction inhibitor | ||
| 6701 | 1A-116 | Jul 2019 |
| Rac1 inhibitor; blocks Rac1-P-Rex1 interaction | ||
| 6757 | t-TUCB | Jul 2019 |
| Potent soluble epoxide hydrolase (sEH) Inhibitor; anti-inflammatory and antinociceptive | ||
| 6904 | Idasanutlin | Jul 2019 |
| Potent MDM2 inhibitor; inhibits MDM2-p53 interaction | ||
| 6924 | Oridonin | Jul 2019 |
| High affinity NLRP3 inflammasome inhibitor | ||
| 6703 | BGP 15 | Jul 2019 |
| PARP inhibitor; cytoprotectant | ||
| 6909 | VH 032 phenol - linker 1 | Jul 2019 |
| VH 032 phenol-alkylC4-amine | ||
| 6969 | cis VH 032, amine dihydrochloride | Jul 2019 |
| Negative control for VH 032, amine (Cat. No. 6462) | ||
| 6910 | VH 032 phenol - linker 2 | Jul 2019 |
| VH 032 phenol-alkylC6-amine | ||
| 6500 | Janelia Fluor® 549, Maleimide | Jul 2019 |
| Cell permeable yellow fluorescent dye; supplied with a maleimide reactive group | ||
| 6228 | H10 | Jul 2019 |
| PARP14 inhibitor; cell-permeable | ||
| 6903 | DPTIP | Jul 2019 |
| Potent and selective N-SMase2 inhibitor; brain penetrant | ||
| 6884 | TC SL C5 | Jul 2019 |
| Metastasis-associated lung adenocarcinoma transcript 1 (Malat1) RNA inhibitor | ||
| 6801 | Tocriscreen Epigenetics Library | Jul 2019 |
| A library of 101 epigenetic compounds (250 μL, 10 mM DMSO solutions) | ||
| 6790 | GSK 126 | Jul 2019 |
| Very high affinity and selective EZH2 inhibitor | ||
| 6960 | ABT 199 | Jul 2019 |
| Selective, high affinity Bcl-2 inhibitor; orally bioavailable | ||
| 6877 | VU 0134992 | Jul 2019 |
| Kir4.1 blocker | ||
| 6908 | TR 14035 | Jul 2019 |
| Potent integrin α4β7 and α4β1 (VLA-4) antagonist; orally bioavailable | ||
| 6874 | AMG 333 | Jul 2019 |
| Potent and selective TRPM8 antagonist; active in vivo | ||
| 6956 | Galunisertib | Jun 2019 |
| ALK4 and ALK5 (TGFβRI) inhibitor | ||
| 6934 | 673 A | Jun 2019 |
| ALDH1A inhibitor; depletes CD133+ cancer stem cells (CSC) | ||
| 6957 | Reparixin L-lysine salt | Jun 2019 |
| Potent CXCR1 and CXCR2 allosteric antagonist | ||
| 6521 | I-BET 762 | Jun 2019 |
| Potent and high affinity BRD inhibitor; anti-inflammatory; orally bioavailable. | ||
| 6966 | Thalidomide - linker 13 | Jun 2019 |
| Thalidomide-PEG1-ethylamine | ||
| 6968 | Thalidomide - linker 15 | Jun 2019 |
| Thalidomide-alkylC6-amine | ||
| 6887 | ML 335 | Jun 2019 |
| Selective K2P2.1 (TREK-1) and K2P10.1 (TREK-2) activator | ||
| 6967 | Thalidomide - linker 14 | Jun 2019 |
| Thalidomide-PEG2-ethylamine | ||
| 6561 | BAY 6035 | Jun 2019 |
| Potent and selective SMYD3 inhibitor | ||
| 6948 | CRBN-6-5-5-VHL | Jun 2019 |
| Potent and selective cereblon degrader; cell-permeable | ||
| 6905 | Ceritinib | Jun 2019 |
| Highly potent ALK inhibitor; also potently inhibits IR, IGF1R, STK22D and FLT3 | ||
| 6917 | Thalidomide - linker 9 | Jun 2019 |
| Thalidomide-alkylC4-amine | ||
| 6713 | ZXH 3-26 | Jun 2019 |
| Potent and selective BRD4 degrader | ||
| 6716 | Pomalidomide - linker 4 | Jun 2019 |
| Pomalidomide-alkylC5-amine | ||
| 6489 | Ocean Blue, SE | Jun 2019 |
| Blue fluorescent dye; supplied as NHS ester | ||
| 6963 | Pomalidomide - linker 8 | Jun 2019 |
| Pomalidomide-PEG4-ethylamine | ||
| 6854 | LY 3009120 | Jun 2019 |
| Potent pan-Raf kinase inhibitor | ||
| 6837 | GSK 923295A | May 2019 |
| Potent and selective centromere associated protein E (CENP-E) allosteric inhibitor | ||
| 6885 | PU 23 | May 2019 |
| Multidrug resistance protein (MRP) 4 inhibitor | ||
| 6665 | BI 9321 | May 2019 |
| Nuclear receptor-binding SET domain (NSD) 3 antagonist; selectively binds PWWP1 domain | ||
| 6778 | S 38093 | May 2019 |
| Selective H3 antagonist and inverse agonist; also σ1 receptor antagonist; antinociceptive | ||
| 6495 | AM 12 | May 2019 |
| TRPC5 inhibitor | ||
| 6926 | Fenoprofen calcium | May 2019 |
| Positive allosteric modulator of MC3 receptors; exhibits biased signaling | ||
| 6872 | BQCA | May 2019 |
| Positive allosteric modulator of M1 receptors | ||
| 6891 | PND 1186 | May 2019 |
| Potent FAK inhibitor; orally bioavailable | ||
| 6493 | A 317491 sodium salt | May 2019 |
| Selective, high affinity P2X3 and P2X2/3 receptor antagonist; antinociceptive | ||
| 6433 | GSK 1016790A | May 2019 |
| Potent TRPV4 agonist; active in vivo | ||
| 6898 | Mitochondrial fusion promoter M1 | May 2019 |
| Mitochondrial fusion promoter | ||
| 6835 | ABT 737 | May 2019 |
| Bcl-2 family inhibitor; mimics BH3 and induces apoptosis in cancer cell lines | ||
| 6782 | Indisulam | May 2019 |
| Molecular glue; pre-mRNA splicing modulator | ||
| 6313 | A 33 | May 2019 |
| Potent and selective PDE4B inhibitor | ||
| 6861 | Anle138b | May 2019 |
| Oligomeric aggregation inhibitor; inhibits prion protein and α-synuclein aggregate formation | ||
| 6817 | BAY 8002 | May 2019 |
| Potent dual MCT1/2 inhibitor; orally bioavailable |